Non-coding RNAs in renal cell carcinoma: Implications for drug resistance - 17/06/23


Abstract |
Renal cell carcinoma (RCC) represents a malignant tumor of the urinary system. Individuals with early-stage RCC could be cured by surgical treatment, but a considerable number of cases of advanced RCC progress to drug resistance. Recently, numerous reports have demonstrated that a variety of non-coding RNAs (ncRNAs) contribute to tumor occurrence and development. ncRNAs can act as oncogenic or tumor suppressor genes to regulate proliferation, migration, drug resistance and other processes in RCC cells through a variety of signaling pathways. Considering the lack of treatment options for advanced RCC after drug resistance, ncRNAs may be a good choice as biomarkers of drug resistance in RCC and targets to overcome drug resistance. In this review, we discussed the effects of ncRNAs on drug resistance in RCC and the great potential of ncRNAs as a biomarker of or a new therapeutic method in RCC.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Drug resistance is a serious challenge for the treatment of advanced and metastatic RCC. |
• | NcRNAs play important roles in RCC drug resistance through a variety of different mechanisms. |
• | NcRNA is expected to become a biomarker and target for RCC to overcome drug resistance. |
Abbreviations : RCC, ccRCC, papRCC, chrRCC, VHL, HIF, ncRNAs, miRNAs, lncRNAs, circRNAs, 3'UTRs, PLIN3, MDR, ATF-2, OCT2, CAPN4, TBCK, SMYD2, CXCR5, AR, CDCA3, ARSR, SRLR, NEAT1, ME1, SNPs, siRNAs, ASOs, ICIs
Keywords : Renal cell carcinoma, Drug resistance, Non-coding RNAs, Biomarkers, MiRNAs
Plan
Vol 164
Article 115001- août 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?